{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:54Z","timestamp":1794273894708,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ophtha.2026.08.039","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:22:05Z","timestamp":1788823325000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-0630","authenticated-orcid":false,"given":"C\u00e9sar A.","family":"Brice\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-5719","authenticated-orcid":false,"given":"Oluwatobi O.","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jwu Jin","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kuenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Q.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Brockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-2419","authenticated-orcid":false,"given":"Nima","family":"Ghadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-0367","authenticated-orcid":false,"given":"Mario","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-676X","authenticated-orcid":false,"given":"Antonio Manuel","family":"Garrido-Hermosilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-1135","authenticated-orcid":false,"given":"Giulio","family":"Barteselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-3479","authenticated-orcid":false,"given":"Santiago","family":"Ortiz-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.08.039_bib1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-8587(25)00066-X","article-title":"Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management","volume":"13","author":"Wiersinga","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1089\/thy.2014.0037","article-title":"What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review","volume":"24","author":"Wickwar","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2026.08.039_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101620","article-title":"Pathophysiology of thyroid-associated orbitopathy","volume":"37","author":"Lee","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib4","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent thyroid eye disease","volume":"31","author":"Patel","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2026.08.039_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ophtha.2026.08.039_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib10","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.08.039_bib12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2025.3350","article-title":"IGF-1R inhibitor IBI311 for the treatment of active thyroid eye disease in Chinese patients: the RESTORE-1 randomized clinical trial","volume":"143","author":"Zhang","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib13","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ophtha.2026.04.022","article-title":"THRIVE: a phase 3, randomized, double-masked, placebo-controlled study of veligrotug for active thyroid eye disease","volume":"133","author":"Yen","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.08.039_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/IOP.0000000000002531","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2026.08.039_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.08.039_bib16","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/thy.2023.0656","article-title":"Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials","volume":"34","author":"Kahaly","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2026.08.039_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib18","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","article-title":"The adverse effects profile of teprotumumab","volume":"108","author":"Stan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/clinem\/dgae417","article-title":"Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment","volume":"110","author":"Huang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2026.08.039_bib20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/IOP.0000000000002569","article-title":"Menstrual irregularities and amenorrhea in thyroid eye disease patients treated with teprotumumab","volume":"40","author":"Terrarosa","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2026.08.039_bib21","article-title":"The role of IL-6 in thyroid eye disease: an update on emerging treatments","volume":"5","author":"Murdock","year":"2025","journal-title":"Front Ophthalmol (Lausanne)"},{"key":"10.1016\/j.ophtha.2026.08.039_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11154-025-10014-5","article-title":"The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease","volume":"27","author":"Ezra","year":"2026","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ophtha.2026.08.039_bib23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/02713683.2021.1912783","article-title":"Association between Clinical Activity Score and serum interleukin-6, interleukin-8 and interleukin-10 during systemic glucocorticoid treatment for active moderate-to-severe Graves\u2019 orbitopathy","volume":"46","author":"Stoynova","year":"2021","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2026.08.039_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib25","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/IOP.0000000000001346","article-title":"Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery","volume":"35","author":"Copperman","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2026.08.039_bib26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib27","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.08.039_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200494","article-title":"Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study","volume":"12","author":"Bennett","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ophtha.2026.08.039_bib29","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s40123-025-01255-3","article-title":"Targeting IL-6 receptor signaling with satralizumab in thyroid eye disease: design of the phase 3 SatraGO-1 and SatraGO-2 trials","volume":"14","author":"Ezra","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ophtha.2026.08.039_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Statist"},{"key":"10.1016\/j.ophtha.2026.08.039_bib31","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.08.039_bib32","article-title":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","volume":"55","author":"Hiromatsu","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ophtha.2026.08.039_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13044-019-0074-0","article-title":"Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves\u2019 orbitopathy","volume":"12","author":"Walasik-Szempli\u0144ska","year":"2019","journal-title":"Thyroid Res"},{"key":"10.1016\/j.ophtha.2026.08.039_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(25)00218-9","article-title":"Thyroid eye disease and the IGF-1 receptor","volume":"13","author":"Smith","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2026.08.039_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ophtha.2026.08.039_bib37","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0171","article-title":"Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis","volume":"13","author":"Bril","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ophtha.2026.08.039_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.ophtha.2026.08.039_bib39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.drudis.2021.03.018","article-title":"Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience","volume":"26","author":"Sellner","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ophtha.2026.08.039_bib40","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology (Oxford)"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026006731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026006731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:55:49Z","timestamp":1791406549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026006731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0161642026006731"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.08.039","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}